MAP - Market Access Podcast

By Dr. Stefan WalzerBusiness Science Medicine Health & Fitness

MAP - Market Access Podcast episodes

September 15, 2021 Prof. Dr. Wagschal - What can we expect from the upcoming elections in Germany?
In this Podcast episode, Dr. Stefan Walzer is speaking to Prof. Dr. Wagschal from the University of Freiburg about the upcoming elections in Germany.
They are discussing latest forecasts and potential policy implications.
Prof. Wagschal also explains limitations of forecasts and dynamics of recent elections.
Another important part is in the potential (new) coalitions and their likely impact on the health care market.
Subscribe at your favourite podcasting platform and for more information about MArS Market Access and Pricing Strategy visit:
marketaccess-pricingstrategy.de
36 min
September 02, 2021 Dr. Mathias Flume - AMNOG will change in 2022, but how?
In this Podcast episode, Dr. Stefan Walzer is talking with Dr. Mathias Flume about the AMNOG process as well as interesting details about the market access process in Germany.
Mathias is a core stakeholder within the regional payer system in Germany at one of the most innovative Statutory Health Insurance Physician Associations (KV Westphalia-Lippe). Mathias brings the payer view into the discussion of 10 years AMNOG. Success or failure?
35 min
August 26, 2021 Dr. Jan Helfrich - Is the AMNOG a success?
Jan is a profound insider of the German reimbursement system, basically knowing all parts and all sites of the processes. He is a trained physician and health economist and worked in hospitals, in one of the largest health insurance funds in Germany as well as in the pharmaceutical industry. Jan brings his knowledge from the various angles into the discussions of 10 years AMNOG. Success or failure?
31 min

About MAP - Market Access Podcast

From the publisher's feed

Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world.

MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries.

The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves.

Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany).

Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition.

Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.